ReviewChinese medicine2026
Targeting the intestinal barrier with traditional Chinese medicine for non-alcoholic fatty liver disease: mechanistic insights and therapeutic perspectives.
Review in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Vitamin D and Intestinal Diseases: Impact on Intestinal Immunity and Gut Barrier Function.Diseases (Basel, Switzerland) · 2026Review
- Review
- Emodin Exerts Dual Hepatoprotective/Hepatotoxic Effects Dependent on Metabolic Microenvironment via Gut-Liver Axis Crosstalk: A Multi-Omics Study in MAFLD and Normal Mice.International journal of molecular sciences · 2026Article
- Tetrandrine, a Major Alkaloid FromFood science & nutrition · 2026Article
- From "Monarch, Minister, Assistant, and Envoy" to "Microbial Dialogue": A Review of Novel Mechanisms by Which Chinese Herb Pairs Improve Metabolic Diseases Through Gut Microbiota Metabolic Regulation.Gastroenterology research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease closely associated with metabolic dysregulation, exhibiting a complex and multifactorial pathogenesis. Recent studies demonstrate that impaired intestinal barrier function, intestinal immune barrier dysfunction, gut microbiota dysbiosis, and their associated metabolites collectively promote energy metabolism dysregulation and systemic inflammatory responses via the gut-liver axis. These interconnected processes represent key drivers in the pathogenesis and progression of NAFLD. Notably, Traditional Chinese Medicine (TCM) offers a promising therapeutic approach for NAFLD by holistically modulating intestinal barrier function, immune responses, and gut microbiota composition via multiple targets and pathways, thereby ameliorating gut dysbiosis and its downstream metabolic and inflammatory sequelae. This review systematically synthesizes the established relationship between NAFLD and intestinal barrier dysfunction. It critically evaluates current research progress on TCM interventions-including single herbs, bioactive constituents, and compound formulas-that target the intestinal barrier for NAFLD management. Key mechanistic insights into TCM efficacy are summarized, focusing on the repair of the intestinal mucosal barrier, modulation of bile acid metabolism and gut microbiota composition, and enhancement of intestinal immune barrier function. Future research should prioritize elucidating the specific molecular mechanisms underpinning TCM-mediated intestinal barrier regulation and strengthening clinical validation, ultimately advancing the scientific foundation for TCM-based NAFLD therapeutics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.